Bioventus director receives stock unit awards

Bioventus Inc. director Susan M. Stalnecker reported equity compensation activity involving restricted stock units (RSUs) and common shares.

Rhea-AI Filing Summary

Bioventus Inc. director Susan M. Stalnecker reported equity compensation activity involving restricted stock units (RSUs) and common shares. On June 3, 2026, she received a grant of 25,146 RSUs, each representing a contingent right to one share of Class A common stock.

On June 2, 2026, 32,282 RSUs vested and were exercised into 32,282 shares of Class A common stock at no cash exercise price. Following these transactions, she holds 138,239 shares of Class A common stock directly, along with 25,146 RSUs that will vest based on future service conditions.

Insider Trade Summary

32,282 shares exercised/converted

Exercise 3 txns

Insider STALNECKER SUSAN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	25,146	$0.00	$0.00
Exercise	Restricted Stock Units	32,282	$0.00	$0.00
Exercise	Class A Common Stock	32,282	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 25,146 contracts (Direct); Class A Common Stock — 138,239 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
2. F2. The RSUs vested on June 2, 2026.
3. F3. The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

Key Figures

RSUs granted: 25,146 RSUs RSUs vested and exercised: 32,282 RSUs Shares acquired from RSUs: 32,282 shares +2 more

5 metrics

RSUs granted 25,146 RSUs Grant on June 3, 2026

RSUs vested and exercised 32,282 RSUs Vested and converted on June 2, 2026

Shares acquired from RSUs 32,282 shares Class A common stock received on vesting

Shares held after transactions 138,239 shares Class A common stock, direct ownership

Outstanding RSUs after grant 25,146 RSUs Contingent rights to Class A common stock

Key Terms

Restricted Stock Units, Class A Common Stock, vested, Annual Meeting of Stockholders

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

vested financial

"The RSUs vested on June 2, 2026."

Annual Meeting of Stockholders regulatory

"on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Bioventus (BVS) director Susan Stalnecker report?

She reported a grant of 25,146 restricted stock units and the vesting and exercise of 32,282 RSUs into 32,282 shares of Class A common stock as equity compensation.

How many Bioventus (BVS) RSUs were granted to Susan Stalnecker?

Susan Stalnecker received a grant of 25,146 restricted stock units. Each RSU represents a contingent right to receive one share of Bioventus Class A common stock, subject to future vesting conditions tied to board service.

When did Susan Stalnecker’s Bioventus (BVS) RSUs vest and convert to shares?

On June 2, 2026, 32,282 restricted stock units vested and were exercised into 32,282 shares of Bioventus Class A common stock, reflecting the completion of prior service-based vesting requirements under her director equity awards.

How many Bioventus (BVS) shares does Susan Stalnecker hold after these transactions?

After the reported transactions, Susan Stalnecker directly holds 138,239 shares of Bioventus Class A common stock, along with 25,146 outstanding restricted stock units that may settle in additional shares when their vesting conditions are satisfied.

Are Susan Stalnecker’s new Bioventus (BVS) RSUs tied to her board service?

Yes. The RSUs are scheduled to vest on the earlier of the day before Bioventus’ first annual stockholders meeting following grant or the first anniversary of grant, provided she continues serving on the board through the vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STALNECKER SUSAN M

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/02/2026		M		32,282	A	$0	138,239	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/02/2026		M			32,282	(2)	(2)	Class A Common Stock	32,282	$0	0	D
Restricted Stock Units	(1)	06/03/2026		A		25,146		(3)	(3)	Class A Common Stock	25,146	$0	25,146	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs vested on June 2, 2026.

3. The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)